Oxalate Excretion Profile in Patients with a Heterozygous Mutation of the AGXT (alanine-glyoxylate Aminotransferase) Gene

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-11

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary hyperoxaluria type I (PH1) is a rare genetic disorder responsible for severe lithiasis leading to progressive deterioration of renal function and end-stage renal failure. PH1 is linked to a deficiency in glyoxylate amino transferase (AGXT), which leads to increased endogenous oxalate synthesis and hyperoxaluria. In the urine, urinary oxalate precipitates with calcium, forming insoluble crystals, leading to lithiasis and the development of nephrocalcinosis.

Non-genetic etiologies of oxalic nephropathy are well known, in particular enteric causes (malabsorptions, bypass, calcium deficiencies, etc.) and sometimes linked to increased oxalate intake in the form of nutritional or vitamin supplements, reinforcing the hypothesis of probably underestimated favouring factors of hyperoxaluria.

Until now, heterozygous patients with a mutation in the AGXT gene were considered asymptomatic. However, there have been several cases of patients with heterozygous AGXT mutations presenting with lithiasis.

Consequently, the characteristics of symptomatic and asymptomatic heterozygous patients will be studied in order to define the elements that would explain the expression of the disease (particularities of the AGXT mutation, presence of another heterozygous mutation or favorable living conditions).

The hypothesis is that there is an increase in hepatic oxalate production in heterozygous patients, which explains why they remain asymptomatic under usual conditions, but could favor stone formation under favorable conditions such as severe calcium deficiency or malabsorption.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

International Registry for Primary Hyperoxaluria

NCT00875823

Primary Hyperoxaluria Nephrocalcinosis Kidney Stones

WITHDRAWN

Rare Kidney Stone Consortium Patient Registry

NCT00588562

Primary Hyperoxaluria Dent Disease Cystinuria +1 more

RECRUITING

Gut Kidney Axis in Enteric Hyperoxaluria

NCT05124886

Enteric Hyperoxaluria

RECRUITING NA

Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate

NCT04571359

Urolithiasis Hyperoxaluria

COMPLETED

Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients

NCT02794649

Oxalate, Primary Hyperoxaluria, Microbiome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperoxaluria (Disorder)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asymptomatic subjects with an AGXT heterozygous mutation

Group Type EXPERIMENTAL

Lithiasis assessment

Intervention Type DIAGNOSTIC_TEST

Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.

Symptomatic subjects with an AGXT heterozygous mutation

Group Type ACTIVE_COMPARATOR

Lithiasis assessment

Intervention Type DIAGNOSTIC_TEST

Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lithiasis assessment

Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presenting an heterozygous mutation on AGXT
* Presenting symptoms (presence or history of stones, nephrocalcinosis) or not

Exclusion Criteria

* Individuals unable to provide 24-hour urine samples.
* Individuals unable to free up a morning for day hospital appointments
* Individuals deprived of liberty by a judicial or administrative decision.
* Adults under a legal protection measure (guardianship, trusteeship).
* Individuals placed under judicial protection.
* Participants enrolled in another study with an ongoing exclusion period
* Pregnant women.
* Individuals not covered by social security

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No